**Core Concept**
Aspirin exerts its cardiovascular benefits through the inhibition of platelet aggregation, which is a critical step in the formation of arterial thrombi that can lead to myocardial infarction. This effect is primarily mediated by the inhibition of cyclooxygenase-1 (COX-1) enzyme in platelets.

**Why the Correct Answer is Right**
Aspirin irreversibly inhibits COX-1, leading to a decrease in the production of thromboxane A2 (TXA2), a potent platelet aggregator. This results in reduced platelet adhesion and aggregation, making it a valuable adjunct in the prevention of arterial thrombosis. The inhibition of COX-1 also leads to an increase in the production of prostacyclin (PGI2), a vasodilator and antiplatelet agent.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect as aspirin does not primarily act through the inhibition of angiotensin-converting enzyme (ACE) to prevent myocardial infarction.
* **Option B:** This option is incorrect as aspirin does not primarily act through the inhibition of the renin-angiotensin-aldosterone system (RAAS) to prevent myocardial infarction.
* **Option C:** This option is incorrect as aspirin does not primarily act through the inhibition of the sympathetic nervous system to prevent myocardial infarction.

**Clinical Pearl / High-Yield Fact**
Aspirin's antiplatelet effect is irreversible, making it essential to avoid its use in patients with bleeding disorders or at risk of bleeding. Additionally, the dose of aspirin used for cardiovascular prophylaxis is typically 81-325 mg once daily.

**Correct Answer:** C.